Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,120
Total Claims
$988K
Drug Cost
590
Beneficiaries
$1,675
Cost/Patient
Risk Score Breakdown 20/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+141%
Opioid rate vs peers
5.4% vs 2.2% avg
+19%
Cost per patient vs peers
$1,675 vs $1,411 avg
+35%
Brand preference vs peers
14.4% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
5.4%
Opioid Rate
492
Opioid Claims
$51K
Opioid Cost
17.7%
Long-Acting Rate
Brand vs Generic
Brand: 1,301 claims · $811K
Generic: 7,741 claims · $173K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 82 | $105K |
| Fluticasone/Umeclidin/Vilanter | 50 | $69K |
| Empagliflozin | 51 | $54K |
| Rivaroxaban | 41 | $48K |
| Tirzepatide | 42 | $46K |
| Apixaban | 61 | $46K |
| Insulin Degludec | 32 | $41K |
| Oxycodone Hcl | 19 | $38K |
| Insulin Glargine,hum.Rec.Anlog | 32 | $26K |
| Dulaglutide | 18 | $26K |
| Insulin Aspart | 29 | $23K |
| Sitagliptin Phosphate | 30 | $22K |
| Linagliptin | 25 | $19K |
| Mirabegron | 25 | $19K |
| Empagliflozin/Metformin Hcl | 17 | $17K |
Prescribing Profile
Patient Profile
73
Avg Age
74%
Female
1.18
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About